Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888870 | 0.82 | MAPT (0.39) | ALDH1A1MAPTMAPK1GAARAB9A | |
| SCHEMBL12203848 | 0.70 | ALDH1A1 (0.51) | ALDH1A1MAPTMAPK1GAARAB9A | |
| SCHEMBL5640362 | 0.69 | RAB9A (0.56) | ALDH1A1MAPTMAPK1GAARAB9A | |
| SCHEMBL23399438 | 0.69 | NR4A3 (0.53) | ALDH1A1MAPTMAPK1GAARAB9A | |
| SCHEMBL2123401 | 0.69 | NR4A3 (0.49) | ALDH1A1MAPTMAPK1GAARAB9A | |
| SCHEMBL12385631 | 0.67 | NR4A3 (0.47) | ALDH1A1MAPTMAPK1GAARAB9A | |
| SCHEMBL33204 | 0.67 | NR4A3 (0.47) | ALDH1A1MAPTMAPK1GAARAB9A | |
| SCHEMBL26042 | 0.67 | NR4A3 (0.54) | ALDH1A1MAPTMAPK1GAARAB9A | |
| SCHEMBL2856262 | 0.67 | ALDH1A1 (0.59) | ALDH1A1MAPTMAPK1GAALMNA | |
| SCHEMBL33201 | 0.66 | NR4A3 (0.49) | ALDH1A1MAPTMAPK1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | ALDH1A1 3589/4885MAPT 3590/4885MAPK1 1878/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | ALDH1A1 3589/4885MAPT 3590/4885MAPK1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.